Neurocrine Biosciences reported $100K in Ordinary Share Capital for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ordinary Share Capital Change
Acadia Pharmaceuticals ACAD:US USD 16K 0
Agios Pharmaceuticals AGIO:US USD 71K 0
Alnylam Pharmaceuticals ALNY:US USD 1.24M 10K
Aptinyx Inc APTX:US USD 677K 0
Biogen BIIB:US USD 100K 0
Biomarin Pharmaceutical BMRN:US USD 186K 0
Cytokinetics CYTK:US USD 94K 1000
Dynavax Technologies DVAX:US USD 128K 1000
Enanta Pharmaceuticals ENTA:US USD 209K 1000
Exelixis EXEL:US USD 324K 1000
Halozyme Therapeutics HALO:US USD 135K 0
Intercept Pharmaceuticals ICPT:US USD 42K 1000
Intra Cellular Therapies ITCI:US USD 9K 0
IONIS PHARMACEUT IONS:US USD 142K 0
Nektar Therapeutics NKTR:US USD 19K 0
Neurocrine Biosciences NBIX:US USD 100K 0
Prothena PRTA:US USD 521K 42K
Repligen RGEN:US USD 556K 1000
Rigel Pharmaceuticals RIGL:US USD 174K 1000
Sarepta Therapeutics SRPT:US USD 9K 0
Teva Pharmaceutical TEVA:IT USD 57M 0
Ultragenyx Pharmaceutical RARE:US USD 70K 0
YTE INCY:US USD 223K 1000